Immune activation by combination human lymphokine-activated killer and dendritic cell therapy

British Journal of Cancer

Volumn 105, Issue 6, 2011, Pages 787-795

  West, E J ^a   Scott, K J ^a   Jennings, V A ^a   Melcher, A A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

dendritic cells; immunotherapy; lymphokine activated killer cells; melanoma; natural killer cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NATURAL KILLER CELL; PHAGOCYTOSIS; PRIORITY JOURNAL;

ADAPTIVE IMMUNITY; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; KILLER CELLS, LYMPHOKINE-ACTIVATED; MELANOMA; TISSUE THERAPY;

EID: 80052448300     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.290     Document Type: Article

References (34)

1. Adam C, King S, Allgeier T, Braumuller H, Luking C, Mysliwietz J, Kriegeskorte A, Busch DH, Rocken M, Mocikat R (2005) DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 106(1): 338-344 (Pubitemid 40967210)
2. Balsamo M, Zambello R, Teramo A, Pedrazzi M, Sparatore B, Scordamaglia F, Pende D, Mingari MC, Moretta L, Moretta A, Semenzato G, Vitale M (2009) Analysis of NK cell/DC interaction in NK-type lymphoprolifera-tive disease of granular lymphocytes (LDGL): role of DNAM-1 and NKp30. Exp Hematol 37(10): 1167-1175
3. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673): 245-252 (Pubitemid 28155090)
4. Berdeja JG, Hess A, Lucas DM, O'Donnell P, Ambinder RF, Diehl LF, Carter-Brookins D, Newton S, Flinn IW (2007) Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clin Cancer Res 13(8): 2392-2399 (Pubitemid 46698589)
5. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, Galy A, Caignard A, Zitvogel L (2004) NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 104(10): 3267-3275 (Pubitemid 39507145)
6. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214: 73-91 (Pubitemid 44707903)
7. Capobianco A, Manfredi AA, Monno A, Rovere-Querini P, Rugarli C (2008) Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells. J Immunother 31(5): 458-465
8. Capobianco A, Rovere-Querini P, Rugarli C, Manfredi AA (2006) Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells. Int J Cancer 119(12): 2861-2869 (Pubitemid 44846238)
9. Chan CJ, Andrews DM, McLaughlin NM, Yagita H, Gilfillan S, Colonna M, Smyth MJ (2010) DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metas-tases. J Immunol 184(2): 902-911
10. Detournay O, Mazouz N, Goldman M, Toungouz M (2005) IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells. Hum Immunol 66(5): 460-468 (Pubitemid 40797544)
11. Dieli F, Caccamo N, Meraviglia S, Ivanyi J, Sireci G, Bonanno CT, Ferlazzo V, La Mendola C, Salerno A (2004) Reciprocal stimulation of gammadelta T cells and dendritic cells during the anti-mycobacterial immune response. Eur J Immunol 34(11): 3227-3235 (Pubitemid 39549401)
12. Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, O'Donnell D, Selby P, Vile R, Melcher A (2006) Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 13(2): 138-149 (Pubitemid 43039906)
13. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, de Bono J, Selby P, Coffey M, Vile R, Melcher A (2008) Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 180(9): 6018-6026
14. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L (1999) Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5(4): 405-411 (Pubitemid 29180578)
15. Friberg DD, Bryant JL, Whiteside TL (1996) Measurements of natural killer (NK) activity and NK-cell quantification. Methods 9(2): 316-326 (Pubitemid 26179430)
16. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155(6): 1823-1841 (Pubitemid 12074218)
17. Iho S, Shau H (1994) Role of enhanced cellular adhesion in IL-6-augmented lymphokine-activated killer-cell function. Scand J Immunol 39(3): 233-240 (Pubitemid 24203076)
18. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, Kirkwood JM, Lotze MT, Herberman RB (2005) Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther 5(10): 1303-1315 (Pubitemid 41503042)
19. Keilholz U, Scheibenbogen C, Brado M, Georgi P, Maclachlan D, Brado B, Hunstein W (1994) Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer 30A(1): 103-105 (Pubitemid 24058099)
20. Kjaergaard J, Hokland ME, Agger R, Skovbo A, Nannmark U, Basse PH (2000) Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals. Cancer Immunol Immunother 48(10): 550-560 (Pubitemid 30004489)
21. Mukaida N (2000) Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 72(4): 391-398
22. Parajuli P, Nishioka Y, Nishimura N, Singh SM, Hanibuchi M, Nokihara H, Yanagawa H, Sone S (1999) Cytolysis of human dendritic cells by autologous lymphokine-activated killer cells: participation of both T cells and NK cells in the killing. J Leukoc Biol 65(6): 764-770 (Pubitemid 29279524)
23. Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA (2008) Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 14(22): 7358-7366
24. Real LM, Jimenez P, Kirkin A, Serrano A, Garcia A, Canton J, Zeuthen J, Garrido F, Ruiz-Cabello F (2001) Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother 49(11): 621-628 (Pubitemid 33783078)
25. Reschner A, Hubert P, Delvenne P, Boniver J, Jacobs N (2008) Innate lymphocyte and dendritic cell cross-talk: a key factor in the regulation of the immune response. Clin Exp Immunol 152(2): 219-226 (Pubitemid 351520908)
26. Rosenberg SA (1988) Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. Important Adv Oncol: 217-257
27. Schmidt J, Eisold S, Buchler MW, Marten A (2004) Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother 53(11): 1018-1026 (Pubitemid 39371746)
28. Semino C, Angelini G, Poggi A, Rubartelli A (2005) NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106(2): 609-616 (Pubitemid 40981258)
29. Srivastava S, Lundqvist A, Childs RW (2008) Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy 10(8): 775-783
30. Takahashi T, Chiba S, Nieda M, Azuma T, Ishihara S, Shibata Y, Juji T, Hirai H (2002) Cutting edge: analysis of human V alpha 24+CD8+ NK T cells activated by alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 168(7): 3140-3144 (Pubitemid 34250371)
31. Valteau-Couanet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Benard J, Beaujean F, Boccaccio C, Zitvogel L, Angevin E (2002) Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 100(7): 2554-2561
32. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Arico M, Moretta L, Moretta A (2005) NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 106(2): 566-571 (Pubitemid 40981252)
33. West E, Morgan R, Scott K, Merrick A, Lubenko A, Pawson D, Selby P, Hatfield P, Prestwich R, Fraser S, Eves D, Anthoney A, Twelves C, Beirne D, Patel P, O'Donnell D, Watt S, Waller M, Dietz A, Robinson P, Melcher A (2009) Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. J Immun-other 32(1): 66-78
34. Yano Y, Ueda Y, Itoh T, Fuji N, Okugawa K, Naito K, Imura K, Kohara J, Hayashi T, Nakane K, Matsuura Y, Kawai K, Yamagishi H (2006) A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro. Oncol Rep 16(1): 147-152